CMA Microdialysis AB, Solna, Sweden
Pioneer and global leader in supplying complete clinical microanalysis solutions for exploring and monitoring tissue chemistry as well as solutions for metabolic monitoring, research and automated blood sampling.
Evaluate strategic sale options for the Company – sale of the entire company vs. parcelling of each business unit and selling them in separate transactions.
Harvard Bioscience, Inc. (NASDAQ: HBIO), a global developer, manufacturer and marketer of a broad range of tools to advance life science research and regenerative medicine.
Sale of preclinical microdialysis business unit as well as the CMA Microdialysis trade name. One of four asset sale transactions. Financial terms were not disclosed.
Acted as Financial Advisor to the Board of Directors and management.
- Worked closely with senior management and the Board to divide the Company’s assets and related intellectual property into four separate transactions.
- Prepared separate marketing materials and compiled electronic data room for each transaction.
- Spearheaded negotiations and managed the strategic sales process as well as IP cross-licensing among acquirers while maintaining competitive tension through-out each process.
